Cohance Lifesciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cohance Lifesciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 50% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 66% in 3 years, but profit fell: ₹27 less profit per ₹100 of extra sales. Lower than 95% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹148Over the last 3 years, every ₹100 of reported profit came with ₹148 of operating cash.
Higher than 68% of Healthcare companies in India.
Self-Funding Ratio
2.4×Over the last 3 years its own operating cash covered its investment spending (capex) 2.4 times.
Higher than 74% of Healthcare companies in India.
Cash Locked Ratio
₹40For every ₹100 of sales, ₹40 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹25 tied up three years earlier.
More money tied up than 78% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
−₹27Sales grew 66% in 3 years, but profit fell: ₹27 less profit per ₹100 of extra sales.
Lower than 95% of Healthcare companies in India.
Asset Productivity Ratio
+66% / +191%In 3 years sales changed by +66% while total assets changed by +191%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
3.1×Debt due within a year is covered 3.1 times by its yearly operating cash.
Higher than 65% of Healthcare companies in India.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Higher than 55% of Healthcare companies in India.
Tangible Assets Ratio
76%Of every ₹100 the company owns, ₹76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 88% of Healthcare companies in India.
Tangible Net Worth Ratio
65%Of every ₹100 of net worth, ₹65 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 84% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Cohance Lifesciences Limited owes ₹0.30 for every ₹1 it owns. Net profit fell 63% in the year to Mar 2026, and shrank 24% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
166.2Investors pay ₹166.2 for every ₹1 of Cohance Lifesciences Limited's yearly profit, higher than 96% of Healthcare companies in India.
P/B ratio
4.44The share price is 4.44 times Cohance Lifesciences Limited's book value per share, lower than 54% of Healthcare companies in India.
Market cap
₹17,364 CrThe total market value of all of Cohance Lifesciences Limited's shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,911 CrWhat Cohance Lifesciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹102.23Net worth divided by the number of shares. The share price of ₹453.85 is 4.4 times this, which is the P/B above.
Return on equity (ROE)
2.7%Cohance Lifesciences Limited earned 2.7% on its shareholders' money over the last year, lower than 87% of Healthcare companies in India.
Owes vs Owns
0.30×Cohance Lifesciences Limited owes ₹0.30 for every ₹1 it owns (low), lower than 68% of Healthcare companies in India.
Dividend yield
NoneCohance Lifesciences Limited does not currently pay a dividend.
Revenue growth
-13%Revenue fell 13% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Profit growth
-63%Net profit fell 63% in the year to Mar 2026, and shrank 24% a year on average over 3 years.
Profit margin
8.1%Cohance Lifesciences Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
2.1×Cash from Cohance Lifesciences Limited's business was 2.1× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
7.1×Cohance Lifesciences Limited's operating profit covered its interest costs 7.1 times in the year to Mar 2026.
Cash vs debt
Net debtCohance Lifesciences Limited had ₹80 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Cohance Lifesciences Limited's P/E ratio?
Investors pay ₹166.2 for every ₹1 of Cohance Lifesciences Limited's yearly profit, higher than 96% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cohance Lifesciences Limited: ₹17,364 Cr ÷ ₹3,911 Cr (31 Mar 2026) = 4.4.
What is Cohance Lifesciences Limited's return on equity?
Cohance Lifesciences Limited earned 2.7% on its shareholders' money over the last year, lower than 87% of Healthcare companies in India.
How much does Cohance Lifesciences Limited owe compared with what it owns?
Cohance Lifesciences Limited owes ₹0.30 for every ₹1 it owns (low), lower than 68% of Healthcare companies in India.
Does Cohance Lifesciences Limited pay a dividend?
No. Cohance Lifesciences Limited does not currently pay a dividend.
Is Cohance Lifesciences Limited's revenue growing?
Revenue fell 13% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.